l e t t e r s
Whole-genome analysis approaches are identifying recurrent cancer-associated somatic alterations in noncoding DNA regions. We combined somatic copy number analysis of 12 tumor types with tissue-specific epigenetic profiling to identify significant regions of focal amplification harboring super-enhancers. Copy number gains of noncoding regions harboring super-enhancers near KLF5, USP12, PARD6B and MYC are associated with overexpression of these cancer-related genes. We show that two distinct focal amplifications of super-enhancers 3′ to MYC in lung adenocarcinoma (MYC-LASE) and endometrial carcinoma (MYC-ECSE) are physically associated with the MYC promoter and correlate with MYC overexpression. CRISPR/Cas9-mediated repression or deletion of a constituent enhancer within the MYC-LASE region led to significant reductions in the expression of MYC and its target genes and to the impairment of anchorageindependent and clonogenic growth, consistent with an oncogenic function. Our results suggest that genomic amplification of super-enhancers represents a common mechanism to activate cancer driver genes in multiple cancer types.
Somatic copy number alterations (SCNAs), including chromosome arm-level copy number changes as well as focal amplifications and deletions, are central events in cancer pathogenesis [1] [2] [3] . Analysis of focal SCNAs has led to the identification of many critical cancer driver genes [4] [5] [6] [7] [8] . However, for focal amplifications and deletions that occur outside of coding regions, the identity of specific targets has remained unclear. Noncoding regions harbor cis-regulatory elements, termed enhancers, that are bound by transcription factors and establish lineage-specific expression programs that define cellular identity [9] [10] [11] [12] [13] . Enhancers are characterized by the histone modifications monomethylation of histone H3 at lysine 4 (H3K4me1) and acetylation of histone H3 at lysine 27 (H3K27ac), binding of coactivators such as p300 and increased chromatin accessibility as defined by DNase I hypersensitivity [14] [15] [16] [17] [18] [19] . Methods such as chromatin immunoprecipitation sequencing (ChIP-seq) and DNase I hypersensitivity sequencing (DNase-seq) have demonstrated the presence of large clusters of enhancers, termed super-enhancers because of the high level of transcription factor binding associated with these regions [19] [20] [21] [22] [23] [24] . Previously, super-enhancers have been implicated in oncogene activation in cancer through focused analyses of individual tumor types 22, [25] [26] [27] [28] [29] . In this study, we systematically investigate SCNAs of noncoding regions on a pan-cancer scale and provide evidence suggesting that focal amplifications of super-enhancers are a common mechanism for upregulating the expression of cancer driver genes.
Statistical methods such as GISTIC (Genomic Identification of Significant Targets in Cancer) 2, 30 have been developed to identify genomic regions that are recurrently amplified or deleted across cancer types. We examined GISTIC analysis of The Cancer Genome Atlas (TCGA) copy number results for 10,534 samples across 29 tumor types and identified noncoding focal amplification peaks in 19 of these tumor types after filtering out amplicons containing genes in the RefSeq database ( Fig. 1a and Supplementary Table 1 ). For 12 of the 19 tumor types, H3K27ac ChIP-seq data from corresponding tissue or cell lines were available from either public data sets such as the Encyclopedia of DNA Elements (ENCODE) and the Roadmap Epigenomics project [20] [21] [22] 31 or our own collection ( Supplementary Table 2 ). Of the 55 focally amplified noncoding regions identified by our analysis, we found six tissue-specific focal amplification peaks harboring super-enhancers as defined by previous criteria 22, 24, 32 (Fig. 1b) .
The six focally amplified super-enhancers reside in four distinct genomic loci. The focal amplification on chromosome 13q identified in head and neck squamous cell carcinoma (~110 kb, chr. 13: 73,880,690-73,990,596) and esophageal carcinoma (~162 kb, chr. 13: 73,880,413-74,042,621) is located between the Krüppel-like transcription factors KLF5 and KLF12 (Fig. 1c) . ChIP-seq profiling of H3K27ac in the head and neck squamous cell carcinoma cell line BICR-31 showed that the focal amplification harbored a cluster of three super-enhancers, which we termed KLF5-HNSE (KLF5 head and neck squamous cell carcinoma super-enhancers). The expression of KLF5 but not KLF12 was significantly higher in head and neck squamous cell carcinoma tumors with KLF5-HNSE amplification than in those without amplification, suggesting that KLF5 is the Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers target gene ( Fig. 1c and Supplementary Fig. 1 ). In total, ~3% (n = 15) of head and neck squamous cell carcinoma cases had amplification of KLF5-HNSE in the absence of KLF5 gene amplification ( Fig. 1c) . Similarly, the esophageal carcinoma amplicon also harbored a superenhancer as demonstrated by the H3K27ac ChIP-seq profile of esophageal cells, and esophageal carcinoma tumors with this amplicon exhibited a trend toward increased KLF5 expression ( Supplementary  Fig. 2) . In lung adenocarcinomas and lung squamous cell carcinomas, KLF5 is also significantly mutated, with recurrent missense alterations Fig. 1d,e ). CRC tumors containing the chromosome 13q amplicon exhibited significantly higher expression of the nearest gene, USP12, encoding ubiquitin-specific peptidase 12, a deubiquitinating enzyme implicated in prostate cancer 33 (Fig. 1d and Supplementary Fig. 1 ). In liver hepatocellular carcinoma tumors with the chromosome 20q amplicon, the expression of the second nearest gene, PARD6B, rather than the closest gene, PTPN1, was upregulated, suggesting that PARD6B is the target gene ( Fig. 1e and Supplementary Fig. 1 ). PARD6B is part of an intracellular signaling complex involved in cellular polarity, and its overexpression may lead to dysregulation of cell orientation and to cellular transformation 34 .
Frequent noncoding amplifications were identified near the MYC gene, with two distinct focal amplification peaks situated ~450 and ~800 kb 3′ to the MYC oncogene in lung adenocarcinoma and uterine corpus endometrial carcinoma, respectively ( Fig. 2a) . These peaks are distinct from the focally amplified super-enhancer regions ~1.5 Mb and ~1.7 Mb 3′ to MYC previously identified in T cell acute lymphoblastic leukemia (T-ALL) and acute myeloid leukemia (AML), respectively 25, 29 . The lung adenocarcinoma peak (chr. 8: 129,166,547-129,190 ,290) encompasses a 23-kb noncoding region that is part of 
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Step l e t t e r s npg l e t t e r s a super-enhancer, as defined by the H3K27ac ChIP-seq profile from A549 lung adenocarcinoma cells, which we refer to as MYC-LASE (MYC lung adenocarcinoma super-enhancer). In total, ~17% of lung adenocarcinoma cases (n = 86) had a, focal amplification of MYC-LASE co-occurring with MYC amplification, whereas ~2% of cases (n = 11) had a focal amplification of MYC-LASE without concurrent amplification of MYC ( Fig. 2a) . Four of 52 (~8%) lung adenocarcinoma cell lines profiled for copy number alterations by the Cancer Cell Line Encyclopedia (CCLE) project 35 also had focal amplification of MYC-LASE in the absence of MYC amplification ( Supplementary  Fig. 3 ). Analysis of rearrangements in whole-genome sequencing data from 70 lung adenocarcinoma tumor-normal pairs 6, 36 identified two tumors with somatic focal amplification of MYC-LASE occurring as a tandem duplication event ( Fig. 2b) . We performed H3K27ac ChIPseq in two additional lung adenocarcinoma cell lines, NCI-H2009 and NCI-H358, the lung squamous cell carcinoma cell line HCC95 and the small cell lung carcinoma cell line NCI-H2171 and validated that MYC-LASE is part of a lung adenocarcinoma-specific super-enhancer ( Fig. 2c and Supplementary Fig. 3) .
The endometrial carcinoma peak (chr. 8: 129,543,949-129,554,294) encompasses a 10-kb noncoding region that harbors a super-enhancer, as defined by the H3K27ac ChIP-seq profile of the endometrial carcinoma cell line Ishikawa (Fig. 2d) , which we refer to as MYC-ECSE (MYC endometrial carcinoma super-enhancer). Approximately 10% of cases (n = 54) had focal amplification of both MYC-ECSE and MYC, whereas ~4% of cases (n = 20) had focal amplification of only MYC-ECSE (Fig. 2a) . The H3K27ac and p300 ChIP-seq profiles of MYC-LASE and MYC-ECSE indicate that each super-enhancer is active only in cell lines from each respective tumor type ( Fig. 2c,d and Supplementary Fig. 4 ).
Distal enhancers regulate target gene expression through chromatin loops that connect enhancers with target gene promoters [37] [38] [39] . We performed chromosome conformation capture (3C) assays in A549 and Ishikawa cells and found that MYC-LASE physically interacted with the MYC promoter only in A549 cells and, reciprocally, that MYC-ECSE physically interacted with the MYC promoter only in Ishikawa cells ( Fig. 2e) . In addition, tumors with amplification of MYC alone or MYC-LASE or MYC-ECSE alone had higher MYC expression than tumors lacking either amplification (Fig. 2f) . These results suggest that both MYC-LASE and MYC-ECSE drive MYC expression through lineage-specific chromatin loops.
To determine whether copy number gain of super-enhancers drives oncogene expression and tumorigenesis, we focused on MYC-LASE. The binding profile for p300, a marker for enhancer activity 14 , identified five constituent enhancers (e1-e5) within MYC-LASE in A549 and NCI-H2009 cells, which overlapped with H3K27ac enrichment and DNase I hypersensitivity ( Fig. 3a) . Of the five constituent enhancers, the e3 enhancer was associated with the highest p300 binding as well as the greatest DNase I hypersensitivity (Fig. 3a) . In luciferase reporter assays in A549, NCI-H358 and NCI-H2009 cells, the e3 enhancer was also found to have the strongest activity (Fig. 3b) . In contrast, MYC-LASE had no detectable enhancer activity in HEK293 cells, confirming that this super-enhancer is specific to lung adenocarcinoma ( Supplementary Fig. 5 ). Duplication of the e3 enhancer in the luciferase reporter construct resulted in >2-fold higher luciferase expression relative to the construct with a single copy of e3, indicating that an increase in copy number of the enhancer region may upregulate target gene expression ( Fig. 3c) .
We next aimed to identify the transcription factors that are required for the lung adenocarcinoma-specific activity of the e3 enhancer. We tested ~350-bp fragments of the ~1.5-kb e3 region in luciferase reporter assays and discovered that a minimal ~148-bp region (mini-e3) was responsible for the preponderance of e3 enhancer activity (Fig. 4a) . Transcription factor motif analysis using the ENCODE motif data set 40 identified GATA3, FOXA1, NFE2L2 and CEBPβ as candidate factors capable of binding to mini-e3 ( Fig. 4b) . Deletion of specific transcription factor binding motif sequences within mini-e3 demonstrated that the NFE2L2 and CEBPβ motifs are necessary to npg l e t t e r s maintain maximal e3 enhancer activity (Fig.  4c) . Short interfering RNA (siRNA)-mediated knockdown of NFE2L2 and CEBPB in A549 cells led to a significant reduction in e3-driven luciferase reporter activity as compared to exposure to control siRNAs ( Fig.  4d and Supplementary Fig. 6 ). Binding of NFE2L2 and CEBPβ to the super-enhancer was subsequently confirmed by ChIP-seq, with the greatest enrichment at the e3 constituent enhancer (Fig. 4e) .
To investigate the functional role of the amplified e3 enhancer region, we first targeted catalytically inactive Cas9 (dCas9) fused to the Krüppel-associated box (KRAB) transcriptional repressor domain 41, 42 to inhibit e3 enhancer activity in NCI-H2009 lung adenocarcinoma cells, which contain four copies of MYC-LASE. Targeting KRAB-dCas9 to the e3 enhancer using two independent single guide RNAs (sgRNAs) resulted in a marked decrease in H3K27ac, as compared to cells expressing a control, non-targeting sgRNA or KRAB-dCas9 only (Fig. 5a) . A significant reduction (~50%) in MYC gene expression was npg l e t t e r s also observed after KRAB-dCas9-mediated repression, confirming MYC as a target gene of the e3 enhancer ( Fig. 5b and Supplementary  Fig. 7) . Furthermore, comparison of RNA sequencing (RNA-seq) data with gene expression signatures [43] [44] [45] [46] for MYC using Gene Set Enrichment Analysis (GSEA) 47 demonstrated that repression of the e3 enhancer is associated with a significant decrease in expression of MYC target genes (Fig. 5c) . Finally, repression of the e3 enhancer led to a significant decrease in both anchorage-independent and clonogenic growth (Fig. 5d,e and Supplementary Fig. 8 ), suggesting that activity of the e3 enhancer is critical for the tumorigenicity of lung adenocarcinoma cells. We also used the CRISPR/Cas9 system to specifically delete the e3 enhancer in NCI-H2009 cells. Two independent pairs of sgRNAs were used to target Cas9 to the boundaries of the e3 enhancer. Deletion of e3 was detected by PCR in cells transduced with either pair of e3-targeting sgRNAs but not in cells transduced with a pair of non-targeting sgRNAs (Fig. 6a-c) . Deletion of the e3 enhancer region resulted in a ~30% reduction in MYC expression ( Fig. 6d) and a significant impairment of both anchorage-independent and clonogenic growth (Fig. 6e,f and Supplementary Fig. 9) . These results suggest that copy number gain of the e3 enhancer region drives MYC overexpression, which contributes to tumorigenic phenotype.
MYC overexpression has been observed as a consequence of rearrangements with the IGH locus in Burkitt lymphoma 22, 48 (Fig. 6g , lower left) as well as amplifications of the MYC gene itself in several tumor types 2 (Fig. 6g, lower left and middle) . Similar to our findings, focal amplification of different super-enhancer regions downstream of MYC have been reported in T-ALL and AML 25, 29 . Collectively, these data suggest that copy number gain of super-enhancers is highly lineage specific but may be a common mechanism for upregulating MYC expression in diverse types of cancer ( Fig. 6g, lower right) .
Chromosomal rearrangements that result in the placement of a superenhancer adjacent to an oncogene have been described in multiple myeloma, leukemia, medulloblastoma and glioblastoma 22, 26, 28, 49 . Here we systematically investigate another somatic structural alterationfocal copy number amplification-through pan-cancer analysis of 10,534 tumors, integrating genomic, epigenomic and transcriptomic data. We report six super-enhancer regions that are focally amplified across different cancer types. These super-enhancer amplifications are associated with overexpression of the MYC oncogene as well as the KLF5, USP12 and PARD6B genes. Thus, focal amplification of super-enhancers represents a new class of structural alterations with functional implications in cancer. Further identification and characterization of these events through whole-genome and long-read sequencing approaches may yield insights into mechanisms of tumorigenesis and provide novel targets for therapeutic intervention.
URLs. TCGA copy number portal, http://www.broadinstitute.org/ tcga; MIT CRISPR Design tool, http://crispr.mit.edu/.
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